FIELD: chemistry.
SUBSTANCE: invention relates to biotechnology, specifically to the preparation of polypeptide complexes having cytotoxicity against cancer cells, which can be used in medicine. By replacing the antigen-binding domain, a polypeptide complex is obtained, which comprises a cancer antigen-binding domain, any of the Fc domains of SEQ ID NO: 23-26 with mutations and a CD3-binding domain, as well as a polynucleotide encoding said polypeptide complex, an expression vector thereof, a host cell for production thereof, and a therapeutic agent comprising said complex.
EFFECT: invention makes it possible to obtain a novel polypeptide complex that retains strong anticancer cytotoxicity and improved safety characteristics, and has a long half-life in the blood.
21 cl, 26 dwg, 3 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2011 |
|
RU2774414C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2812875C1 |
| METHOD OF MODIFICATION OF POLYPEPTIDE FOR PURIFICATION OF POLYPEPTIDE MULTIMERS | 2010 |
|
RU2606264C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
| CELL DAMAGE INDUCING THERAPEUTIC MEDICINAL PRODUCT FOR ANTICANCER THERAPY | 2017 |
|
RU2746754C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| BISPECIFIC ANTIBODIES SPECIFIC TO PD1 AND TIM3 | 2016 |
|
RU2729371C1 |
| BISPECIFIC ANTIBODY AND ITS USE | 2019 |
|
RU2785292C2 |
